Followers | 827 |
Posts | 119535 |
Boards Moderated | 15 |
Alias Born | 09/05/2002 |
Wednesday, May 17, 2023 4:57:53 PM
https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html
IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.
BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).
Please see #msg-168259768 for related info.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent IMMP News
- Immutep Quarterly Activities Report Q3 FY24 • GlobeNewswire Inc. • 04/29/2024 12:00:00 PM
- Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B • GlobeNewswire Inc. • 04/24/2024 12:00:00 PM
- Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- Immutep Announces First Clinical Data from 90mg Dosing of Efti • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 09:01:56 PM
- Immutep Quarterly Activities Report Q2 FY24 • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 12/21/2023 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 11:06:56 AM
- Immutep Receives A$2.6 million R&D Tax Incentive from French Government • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial • GlobeNewswire Inc. • 11/22/2023 01:00:00 PM
- Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer • GlobeNewswire Inc. • 11/06/2023 01:00:00 PM
- Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 10:06:58 AM
- Immutep to Participate in November Investor Events • GlobeNewswire Inc. • 11/02/2023 12:00:00 PM
- Immutep Quarterly Activities Report Q1 FY24 • GlobeNewswire Inc. • 10/31/2023 12:00:00 PM
- Immutep receives ~A$1.13 million R&D Tax Incentive • GlobeNewswire Inc. • 10/25/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/25/2023 10:07:25 AM
- Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023 • GlobeNewswire Inc. • 10/24/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 10:35:30 AM
- Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Immutep Announces Publication of Abstracts at ESMO Congress 2023 • GlobeNewswire Inc. • 10/16/2023 12:00:00 PM
- Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting • GlobeNewswire Inc. • 10/03/2023 12:00:00 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM